Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2021 | May 01, 2021 | |
Document and Entity Information | ||
Entity Registrant Name | IRADIMED CORP | |
Entity Central Index Key | 0001325618 | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2021 | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Entity File Number | 001-36534 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 73-1408526 | |
Entity Address, Address Line One | 1025 Willa Springs Drive | |
Entity Address, City or Town | Winter Springs | |
Entity Address, State or Province | FL | |
Entity Address, Postal Zip Code | 32708 | |
City Area Code | 407 | |
Local Phone Number | 677-8022 | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Trading Symbol | IRMD | |
Title of 12(b) Security | Common stock, par value $0.0001 | |
Security Exchange Name | NASDAQ | |
Entity Common Stock, Shares Outstanding | 12,312,481 | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Interactive Data Current | Yes | |
Document Fiscal Year Focus | 2021 | |
Document Fiscal Period Focus | Q1 |
BALANCE SHEETS
BALANCE SHEETS - USD ($) | Mar. 31, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash and cash equivalents | $ 50,801,629 | $ 50,068,728 |
Accounts receivable, net of allowance for doubtful accounts of $48,185 as of March 31, 2021 and $46,484 as of December 31, 2020 | 4,564,172 | 4,574,932 |
Investments | 1,902,940 | 1,909,368 |
Inventory, net | 4,640,556 | 3,933,987 |
Prepaid expenses and other current assets | 929,382 | 771,666 |
Prepaid income taxes | 2,373,828 | 2,477,211 |
Total current assets | 65,212,507 | 63,735,892 |
Property and equipment, net | 2,126,079 | 2,120,148 |
Intangible assets, net | 976,382 | 960,885 |
Operating lease right-of-use asset, net | 2,652,533 | 2,715,030 |
Deferred income taxes, net | 985,336 | 1,272,672 |
Other assets | 236,089 | 261,993 |
Total assets | 72,188,926 | 71,066,620 |
Current liabilities: | ||
Accounts payable | 618,217 | 657,054 |
Accrued payroll and benefits | 1,232,683 | 1,714,782 |
Other accrued taxes | 77,593 | 103,981 |
Warranty reserve | 96,448 | 90,054 |
Deferred revenue | 2,203,589 | 1,949,259 |
Current portion of operating lease liability | 259,553 | 255,698 |
Other current liabilities | 146,435 | 146,435 |
Total current liabilities | 4,634,518 | 4,917,263 |
Deferred revenue | 2,083,342 | 2,305,413 |
Operating lease liability, less current portion | 2,392,980 | 2,459,332 |
Total liabilities | 9,110,840 | 9,682,008 |
Stockholders' equity: | ||
Common stock; $0.0001 par value; 31,500,000 shares authorized; 12,312,184 shares issued and outstanding as of March 31, 2021 and 12,308,432 shares issued and outstanding as of December 31, 2020 | 1,231 | 1,231 |
Additional paid-in capital | 23,988,337 | 23,676,843 |
Retained earnings | 39,056,300 | 37,669,451 |
Accumulated other comprehensive income | 32,218 | 37,087 |
Total stockholders' equity | 63,078,086 | 61,384,612 |
Total liabilities and stockholders' equity | $ 72,188,926 | $ 71,066,620 |
BALANCE SHEETS (Parenthetical)
BALANCE SHEETS (Parenthetical) - USD ($) | Mar. 31, 2021 | Dec. 31, 2020 |
BALANCE SHEETS | ||
Accounts receivable, allowance for doubtful accounts | $ 48,185 | $ 46,484 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 31,500,000 | 31,500,000 |
Common stock, shares issued | 12,312,184 | 12,308,432 |
Common stock, shares outstanding | 12,312,184 | 12,308,432 |
STATEMENTS OF OPERATIONS
STATEMENTS OF OPERATIONS - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
STATEMENTS OF OPERATIONS | ||
Revenue | $ 9,223,996 | $ 8,677,541 |
Cost of revenue | 2,161,680 | 2,213,730 |
Gross profit | 7,062,316 | 6,463,811 |
Operating expenses: | ||
General and administrative | 2,430,369 | 2,862,727 |
Sales and marketing | 2,379,124 | 2,433,567 |
Research and development | 475,817 | 430,282 |
Total operating expenses | 5,285,310 | 5,726,576 |
Income from operations | 1,777,006 | 737,235 |
Other (expense) income, net | (5,663) | 98,502 |
Income before provision for income taxes | 1,771,343 | 835,737 |
Provision for income tax expense (benefit) | 384,494 | (933,474) |
Net income | $ 1,386,849 | $ 1,769,211 |
Net income per share: | ||
Basic (in dollars per share) | $ 0.11 | $ 0.15 |
Diluted (in dollars per share) | $ 0.11 | $ 0.14 |
Weighted average shares outstanding: | ||
Basic (in shares) | 12,310,577 | 11,891,428 |
Diluted (in shares) | 12,521,279 | 12,365,605 |
STATEMENTS OF COMPREHENSIVE INC
STATEMENTS OF COMPREHENSIVE INCOME - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
STATEMENTS OF COMPREHENSIVE INCOME | ||
Net income | $ 1,386,849 | $ 1,769,211 |
Other comprehensive income (loss): | ||
Change in fair value of available-for-sale securities, net of tax (benefit) expense of $(1,559) and $3,442, respectively | (4,869) | 10,433 |
Other comprehensive (loss) income | (4,869) | 10,433 |
Comprehensive income | $ 1,381,980 | $ 1,779,644 |
STATEMENTS OF COMPREHENSIVE I_2
STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
STATEMENTS OF COMPREHENSIVE INCOME | ||
Change in fair value of available-for-sale securities, net of tax expense | $ 1,559 | $ 3,442 |
STATEMENTS OF STOCKHOLDERS' EQU
STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) | Common Stock | Additional Paid-in Capital | Retained Earnings | Accumulated Other Comprehensive (Loss) Income | Total |
Balances at Dec. 31, 2019 | $ 1,177 | $ 19,192,394 | $ 36,300,450 | $ 30,374 | $ 55,524,395 |
Balance (in shares) at Dec. 31, 2019 | 11,765,875 | ||||
Increase (Decrease) in Stockholders' Equity | |||||
Net income | 1,769,211 | 1,769,211 | |||
Other comprehensive income | 10,433 | 10,433 | |||
Stock-based compensation | 568,958 | 568,958 | |||
Net share settlement of restricted stock units | $ 1 | (133,873) | (133,872) | ||
Net share settlement of restricted stock units (in shares) | 14,521 | ||||
Exercise of stock options | $ 19 | 322,160 | 322,179 | ||
Exercise of stock options (in Shares) | 190,541 | ||||
Balances at Mar. 31, 2020 | $ 1,197 | 19,949,639 | 38,069,661 | 40,807 | 58,061,304 |
Balance (in shares) at Mar. 31, 2020 | 11,970,937 | ||||
Balances at Dec. 31, 2020 | $ 1,231 | 23,676,843 | 37,669,451 | 37,087 | 61,384,612 |
Balance (in shares) at Dec. 31, 2020 | 12,308,432 | ||||
Increase (Decrease) in Stockholders' Equity | |||||
Net income | 1,386,849 | 1,386,849 | |||
Other comprehensive income | (4,869) | (4,869) | |||
Stock-based compensation | 347,741 | 347,741 | |||
Net share settlement of restricted stock units | (38,707) | (38,707) | |||
Net share settlement of restricted stock units (in shares) | 3,502 | ||||
Exercise of stock options | 2,460 | 2,460 | |||
Exercise of stock options (in Shares) | 250 | ||||
Balances at Mar. 31, 2021 | $ 1,231 | $ 23,988,337 | $ 39,056,300 | $ 32,218 | $ 63,078,086 |
Balance (in shares) at Mar. 31, 2021 | 12,312,184 |
STATEMENTS OF CASH FLOWS
STATEMENTS OF CASH FLOWS - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Operating activities: | ||
Net income | $ 1,386,849 | $ 1,769,211 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Change in allowance for doubtful accounts | 1,728 | 36,756 |
Change in provision for excess and obsolete inventory | (1,992) | 128,143 |
Depreciation and amortization | 331,794 | 344,784 |
Stock-based compensation | 347,741 | 568,958 |
Deferred income taxes, net | 288,895 | (32,472) |
Changes in operating assets and liabilities: | ||
Accounts receivable | 9,032 | 1,404,704 |
Inventory | (668,361) | (560,996) |
Prepaid expenses and other current assets | (560,508) | (538,093) |
Other assets | 32,059 | (60,614) |
Accounts payable | (75,805) | (266,644) |
Accrued payroll and benefits | (482,099) | (542,834) |
Other accrued taxes | (26,388) | (469,750) |
Warranty reserve | 6,394 | 7,924 |
Deferred revenue | 250,359 | 308,559 |
Prepaid income taxes | 103,383 | (901,001) |
Net cash provided by operating activities | 943,081 | 1,196,635 |
Investing activities: | ||
Purchases of property and equipment | (132,318) | (166,593) |
Capitalized intangible assets | (41,615) | (63,782) |
Net cash used in investing activities | (173,933) | (230,375) |
Financing activities: | ||
Proceeds from exercises of stock options | 2,460 | 322,179 |
Taxes paid related to the net share settlement of equity awards | 38,707 | 133,872 |
Net cash (used in) provided by financing activities | (36,247) | 188,307 |
Net increase in cash and cash equivalents | 732,901 | 1,154,567 |
Cash and cash equivalents, beginning of period | 50,068,728 | 43,481,781 |
Cash and cash equivalents, end of period | 50,801,629 | 44,636,348 |
Supplemental disclosure of cash flow information: | ||
Cash paid for income taxes | 5,195 | |
Operating and short-term lease payments recorded within cash flow from operating activities | $ 118,067 | $ 107,081 |
Basis of Presentation
Basis of Presentation | 3 Months Ended |
Mar. 31, 2021 | |
Basis of Presentation | |
Basis of Presentation | IRADIMED CORPORATION Notes to Unaudited Condensed Financial Statements 1 — Basis of Presentation The accompanying interim condensed financial statements of IRADIMED CORPORATION (“IRADIMED”, the “Company”, “we”, “our”) have been prepared pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally presented in annual financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP") have been condensed or omitted pursuant to such rules and regulations. The interim financial information is unaudited, but reflects all normal adjustments that are, in the opinion of management, necessary for the fair presentation of our financial position, results of operations and cash flows for the interim periods presented. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. These accompanying interim condensed financial statements should be read with the financial statements and related footnotes to financial statements included in our Annual Report on Form 10-K for the year ended December 31, We operate in one reportable segment which is the development, manufacture and sale of MRI compatible medical devices, related accessories, disposables and service for use by hospitals and acute care facilities during MRI procedures. Certain Significant Risks and Uncertainties We market our products to end users in the U.S. and to distributors internationally. Sales to end users in the U.S. are generally made on open credit terms. Management maintains an allowance for potential credit losses. We have deposited our cash and cash equivalents with various financial institutions. Our cash and cash equivalents balances exceed federally insured limits throughout the year. We have not incurred any losses related to these balances. Our products require clearance from the Food and Drug Administration and international regulatory agencies prior to commercialized sales. Our future products may not receive required approvals. If we were denied such approvals, or if such approvals were revoked or delayed or if we were unable to timely renew certain approvals for existing products, it would have a materially adverse impact on our business, results of operations and financial condition. Certain key components of our products essential to their functionality are sole-sourced. Any disruption in the availability of these components would have a materially adverse impact on our business, results of operations and financial condition. COVID-19 Considerations The COVID-19 pandemic caused disruption in global supply and distribution channels and dramatically changed the way companies do business. From the beginning of this global health crisis, our first priority has been the safety and well-being of our employees. We continue to monitor the developments associated with the COVID-19 pandemic and its effects on our employees, customers, supply chain and distribution channels. The ongoing impact of the pandemic depends on a number of factors including the severity and duration of the pandemic and the extent and severity of the impact on our customers, which is uncertain and unpredictable. Our future results of operations and cash flows may suffer adverse effects from delays in payments on outstanding accounts receivable, potential manufacturing, distribution and supply chain disruptions and uncertain demand, and effects of any actions we may take to address financial and operational challenges our customers may face. Our future results will be heavily determined by timely rollout of the vaccines, effectiveness of the vaccines, the duration of the pandemic, its geographic spread, further business disruptions and the overall impact on the global economy. Other risks and uncertainties that we face include, but are not limited to: ● postponement or cancellation of MRI medical procedures and their uncertain return which adversely impacts our business; ● potential temporary or prolonged closure of our office and production facility; ● the health of our employees and ability to meet staffing needs; ● potential new or continued governmental actions that may limit employees’ ability to work; ● civil unrest relating to government, corporate and societal responses to the pandemic; ● volatility in economic conditions and the financial markets, and ● other unanticipated effects that remain unknown. We are actively managing our response to the COVID-19 pandemic and working with our customers, distributors, vendors, and suppliers and assessing the potential effects to our financial position, results of operations and cash flows. As of the date of the issuance of these financial statements, the extent to which COVID-19 may materially impact our financial condition, liquidity, or results of operations in future periods remains uncertain. Recent Accounting Pronouncements Recently Issued Accounting Pronouncements to be Implemented In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Codification Improvements to Topic 326, Financial Instruments - Credit Losses Codification Improvements to Topic 326, Financial Instruments - Credit Losses Financial Instruments - Credit Losses (Topic 326): Targeted Transition Relief Accounting Pronouncements Implemented in 2021 In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes |
Revenue Recognition
Revenue Recognition | 3 Months Ended |
Mar. 31, 2021 | |
Revenue Recognition | |
Revenue Recognition | 2 — Revenue Recognition Disaggregation of Revenue We disaggregate revenue from contracts with customers by geographic region and revenue type as we believe it best depicts the nature, amount, timing and uncertainty of our revenue and cash flow. Revenue information by geographic region is as follows: Three Months Ended March 31, 2021 2020 (unaudited) United States $ 7,272,830 $ 6,322,106 International 1,951,166 2,355,435 Total revenue $ 9,223,996 $ 8,677,541 Revenue information by type is as follows: Three Months Ended March 31, 2021 2020 (unaudited) Devices: MRI compatible IV infusion pump system $ 3,503,347 $ 2,664,834 MRI compatible patient vital signs monitoring systems 2,603,830 2,888,703 Total Devices revenue 6,107,177 5,553,537 Disposables, services and other 2,635,466 2,662,713 Amortization of extended warranty agreements 481,353 461,291 Total revenue $ 9,223,996 $ 8,677,541 Contract Liabilities Our contract liabilities consist of: March 31, December 31, 2021 2020 (unaudited) Advance payments from customers $ 191,227 $ 85,590 Shipments in-transit 218,100 35,013 Extended warranty agreements 3,877,604 4,134,069 Total $ 4,286,931 $ 4,254,672 Changes in the contract liabilities during the periods presented are as follows: Deferred Revenue Contract liabilities, December 31, 2020 $ 4,254,672 Increases due to cash received from customers 681,433 Decreases due to recognition of revenue (649,174) Contract liabilities, March 31, 2021 $ 4,286,931 Deferred Revenue Contract liabilities, December 31, 2019 $ 4,301,887 Increases due to cash received from customers 779,048 Decreases due to recognition of revenue (492,924) Contract liabilities, March 31, 2020 $ 4,588,011 Capitalized Contract Costs Our capitalized contract costs totaled $352,308 and $384,367 as of March 31, 2021 and December 31, 2020, respectively. |
Basic and Diluted Net Income pe
Basic and Diluted Net Income per Share | 3 Months Ended |
Mar. 31, 2021 | |
Basic and Diluted Net Income per Share | |
Basic and Diluted Net Income per Share | 3 — Basic and Diluted Net Income per Share Basic net income per share is based upon the weighted-average number of common shares outstanding during the period. Diluted net income per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Stock options and restricted stock units granted by us represent the only dilutive effect reflected in diluted weighted-average shares outstanding. The following table presents the computation of basic and diluted net income per share: Three Months Ended March 31, 2021 2020 (unaudited) Net income $ 1,386,849 $ 1,769,211 Weighted-average shares outstanding — Basic 12,310,577 11,891,428 Effect of dilutive securities: Stock options 189,933 414,439 Restricted stock units 20,769 59,738 Weighted-average shares outstanding — Diluted 12,521,279 12,365,605 Basic net income per share $ 0.11 $ 0.15 Diluted net income per share $ 0.11 $ 0.14 Stock options and restricted stock units excluded from the calculation of diluted net income per share because the effect would have been anti-dilutive are as follows: Three Months Ended March 31, 2021 2020 (unaudited) Anti-dilutive stock options and restricted stock units 4,902 62,904 |
Inventory
Inventory | 3 Months Ended |
Mar. 31, 2021 | |
Inventory | |
Inventory | 4 — Inventory Inventory consists of: March 31, December 31, 2021 2020 (unaudited) Raw materials $ 3,502,986 $ 3,210,815 Work in process 292,644 207,807 Finished goods 980,607 653,038 Inventory before allowance for excess and obsolete 4,776,237 4,071,660 Allowance for excess and obsolete (135,681) (137,673) Total $ 4,640,556 $ 3,933,987 |
Property and Equipment
Property and Equipment | 3 Months Ended |
Mar. 31, 2021 | |
Property and Equipment | |
Property and Equipment | 5 — Property and Equipment Property and equipment consist of: March 31, December 31, 2021 2020 (unaudited) Computer software and hardware $ 721,008 $ 705,811 Furniture and fixtures 1,226,865 1,226,113 Leasehold improvements 230,351 230,351 Machinery and equipment 1,842,037 1,823,835 Tooling in-process 569,365 470,446 4,589,626 4,456,556 Accumulated depreciation (2,463,547) (2,336,408) Total $ 2,126,079 $ 2,120,148 Depreciation expense of property and equipment was $127,139 and $126,308 for the three months ended March 31, 2021 and 2020, respectively. Property and equipment, net, information by geographic region is as follows: March 31, December 31, 2021 2020 (unaudited) United States $ 1,855,369 $ 1,832,894 International 270,710 287,254 Total property and equipment, net $ 2,126,079 $ 2,120,148 Long-lived assets held outside of the United States consist principally of tooling and machinery and equipment, which are components of property and equipment, net. |
Intangible Assets
Intangible Assets | 3 Months Ended |
Mar. 31, 2021 | |
Intangible Assets | |
Intangible Assets | 6 — Intangible Assets The following table summarizes the components of intangible asset balances: March 31, December 31, 2021 2020 (unaudited) Patents — in use $ 362,162 $ 362,162 Patents — in process 73,648 69,733 Internally developed software — in use 872,218 872,253 Internally developed software — in process 299,357 261,622 Trademarks 27,247 27,247 1,634,632 1,593,017 Accumulated amortization (658,250) (632,132) Total $ 976,382 $ 960,885 Amortization expense of intangible assets was $26,118 and $22,491 for the three months ended March 31, 2021 and 2020, respectively. Expected annual amortization expense for the remaining portion of 2021 and the next five years related to intangible assets is as follows (excludes in process intangible assets): Nine months ending December 31, 2021 $ 75,313 2022 $ 99,700 2023 $ 99,189 2024 $ 98,787 2025 $ 95,849 2026 $ 84,830 |
Investments
Investments | 3 Months Ended |
Mar. 31, 2021 | |
Investments | |
Investments | 7 — Investments Our investments consist of bonds that we have classified as available-for-sale and are summarized in the following tables: March 31, 2021 Gross Gross Unrealized Unrealized Fair Cost Gains Losses Value U.S. corporate bonds $ 1,863,382 $ 39,558 $ — $ 1,902,940 December 31, 2020 Gross Gross Unrealized Unrealized Fair Cost Gains Losses Value U.S. corporate bonds $ 1,863,382 $ 45,986 $ — $ 1,909,368 |
Fair Value Measurements
Fair Value Measurements | 3 Months Ended |
Mar. 31, 2021 | |
Fair Value Measurements | |
Fair Value Measurements | 8 — Fair Value Measurements The fair values of cash equivalents, accounts receivables, net and accounts payable approximate their carrying amounts due to their short duration. The fair value of our assets and liabilities subject to recurring fair value measurements are as follows: Fair Value at March 31, 2021 Quoted Prices Significant in Active Other Significant Market for Observable Unobservable Fair Identical Assets Inputs Inputs Value (Level 1) (Level 2) (Level 3) U.S. corporate bonds $ 1,902,940 $ — $ 1,902,940 $ — Fair Value at December 31, 2020 Quoted Prices Significant in Active Other Significant Market for Observable Unobservable Fair Identical Assets Inputs Inputs Value (Level 1) (Level 2) (Level 3) U.S. corporate bonds $ 1,909,368 $ — $ 1,909,368 $ — Our corporate bonds are valued by a third-party custodian at closing prices from secondary exchanges or pricing vendors on the valuation date. There were no transfers |
Accumulated Other Comprehensive
Accumulated Other Comprehensive Income | 3 Months Ended |
Mar. 31, 2021 | |
Accumulated Other Comprehensive Income | |
Accumulated Other Comprehensive Income | 9 — Accumulated Other Comprehensive Income The components of accumulated other comprehensive income, net of tax, for the three months ended March 31, 2021 and 2020 are as follows: Unrealized (Losses) Gains on Available-For-Sale Securities Balance at December 31, 2020 $ 37,087 Loss on available-for-sale securities, net (4,869) Balance at March 31, 2021 $ 32,218 Balance at December 31, 2019 $ 30,374 Gains on available-for-sale securities, net 10,433 Balance at March 31, 2020 $ 40,807 |
Stock-Based Compensation
Stock-Based Compensation | 3 Months Ended |
Mar. 31, 2021 | |
Stock-Based Compensation | |
Stock-Based Compensation | 10 — Stock-Based Compensation In December 2020, the Company granted 11,891 Performance-Based Restricted Stock Units ("PSUs") to certain employees under a new Long-Term Incentive Plan ("LTIP") for the three-year cycle ending December 7, 2023, which was adopted under the Company's Amended and Restated 2014 Equity Incentive Plan. Each PSU represents the right to receive one share of the Company's common stock. Payouts of the PSUs for the cycle ending December 7, 2023 will be based on the Company's total shareholder return compared to a pre-defined peer group. For purposes of the LTIP, total shareholder return is calculated as the share price at the end of the performance period, including the reinvestment of any dividends during the performance period, as compared to the share price at the beginning of the performance period. The payout range for participants will be between 0% and 200%, depending on the Company's performance against the peer group. The grant date fair value of the PSUs was $29.53 per unit, which was calculated using a Monte-Carlo simulation model with an expected term of three years and a risk-free interest rate of 0.2%. The Monte-Carlo simulation incorporated the volatility and dividend yield for the Company and each member of the peer group individually. Peer group volatilities ranged from 39.9% to 89.4% and dividend yields ranged from 0.0% to 1.23%. The volatility and dividend yield used for the Company was 51.0% and 0.0%, respectively. Stock-based compensation was recognized as follows in the Condensed Statements of Operations: Three Months Ended March 31, 2021 2020 (unaudited) Cost of revenue $ 54,211 $ 58,254 General and administrative 180,204 362,152 Sales and marketing 81,935 130,955 Research and development 31,391 17,597 Total $ 347,741 $ 568,958 As of March 31, 2021, we had $2,867,766 of unrecognized compensation cost related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 2.7 years. As of March 31, 2021, we had $247,002 of unrecognized compensation cost related to unvested PSUs, which is expected to be recognized over a weighted-average period of 2.7 years. The following table presents a summary of our stock-based compensation activity for the three months ended March 31, 2021 (shares): Performance Based Stock Restricted Restricted Options Stock Units Stock Units Outstanding beginning of period 230,510 151,139 11,891 Awards granted — 8,920 — Awards exercised/vested (250) (5,157) — Awards canceled — (9,346) (2,546) Outstanding end of period 230,260 145,556 9,345 |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2021 | |
Income Taxes | |
Income Taxes | 11 — Income Taxes For the three months ended March 31, 2021, we recorded a provision for income tax expense of $384,494. Our effective tax rate was 21.7 percent and differed from the U.S. Federal statutory rate primarily due to U.S. state income tax expense, partially offset by benefits from foreign derived intangible income and research and development tax credits. For the three months ended March 31, 2020, we recorded a provision for income tax benefit of $(933,474). Our effective tax rate was (111.7) percent and differed from the U.S. Federal statutory rate primarily due to discrete items related to tax benefits associated with stock-based compensation and a U.S. state tax benefit. Additionally, we recognized a benefit in our effective tax rate resulting from the Coronavirus Aid, Relief, and Economic Security Act, which allowed us to carryback the net operating loss to years prior to the enactment of the Tax Cuts and Jobs Act. As of March 31, 2021, and December 31, 2020, we had not identified or accrued for any uncertain tax positions. We are currently unaware of any uncertain tax positions that could result in significant payments, accruals or other material deviations in this estimate over the next 12 months. We believe that our tax positions comply in all material respects with applicable tax law. However, tax law is subject to interpretation, and interpretations by taxing authorities could be different from ours, which could result in the imposition of additional taxes and penalties. We file tax returns in the United States Federal jurisdiction and many U.S. state jurisdictions. Our returns are not currently under examination by the Internal Revenue Service. The Company remains subject to income tax examinations for our United States Federal and certain U.S. state income taxes for 2017 and subsequent years and various other U.S. state income taxes for 2016 and subsequent years. |
Leases
Leases | 3 Months Ended |
Mar. 31, 2021 | |
Leases | |
Leases | 12 — Leases We have one material lease contract outstanding. In January 2014, we entered into a non-cancelable operating lease, commencing July 1, 2014, for our manufacturing and headquarters facility in Winter Springs, Florida owned by Susi, LLC, an entity controlled by our President, Chief Executive Officer, and Chairman of the Board, Roger Susi. Pursuant to the terms of our lease for this property, the monthly base rent is $34,133, adjusted annually for changes in the consumer price index. Under the terms of the lease, we are responsible for property taxes, insurance and maintenance expenses. Prior to May 31, 2019, the expiration date of the initial lease term, and pursuant to the terms of the lease contract, we renewed the lease for an additional five years, resulting in a new lease expiration date of May 31, 2024. Unless advance written notice of termination is timely provided, the lease will automatically renew for one additional successive term of five years beginning in 2024, and thereafter, will be renewed for successive terms of one year each.We concluded that we would exercise the remaining five-year residual value guarantee Operating lease cost recognized in the Condensed Statements of Operations is as follows: Three Months Ended March 31, 2021 2020 Cost of revenue $ 51,095 $ 46,535 General and administrative 50,556 46,044 Sales and marketing 2,859 2,604 Research and development 7,922 7,215 Total $ 112,432 $ 102,398 Lease costs for short-term leases were immaterial for the three months ended March 31, 2021 and 2020. Maturity of operating lease liability as of March 31, 2021 is as follows: Nine months ending December 31, 2021 $ 307,197 2022 409,596 2023 409,596 2024 409,596 2025 409,596 Thereafter 1,399,454 Total lease payments 3,345,035 Imputed interest (692,502) Present value of lease liability $ 2,652,533 |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2021 | |
Commitments and Contingencies | |
Commitments and Contingencies | 13 — Commitments and Contingencies Purchase commitments. Legal matters. |
Basis of Presentation (Policies
Basis of Presentation (Policies) | 3 Months Ended |
Mar. 31, 2021 | |
Basis of Presentation | |
Certain Significant Risks and Uncertainties | Certain Significant Risks and Uncertainties We market our products to end users in the U.S. and to distributors internationally. Sales to end users in the U.S. are generally made on open credit terms. Management maintains an allowance for potential credit losses. We have deposited our cash and cash equivalents with various financial institutions. Our cash and cash equivalents balances exceed federally insured limits throughout the year. We have not incurred any losses related to these balances. Our products require clearance from the Food and Drug Administration and international regulatory agencies prior to commercialized sales. Our future products may not receive required approvals. If we were denied such approvals, or if such approvals were revoked or delayed or if we were unable to timely renew certain approvals for existing products, it would have a materially adverse impact on our business, results of operations and financial condition. Certain key components of our products essential to their functionality are sole-sourced. Any disruption in the availability of these components would have a materially adverse impact on our business, results of operations and financial condition. COVID-19 Considerations The COVID-19 pandemic caused disruption in global supply and distribution channels and dramatically changed the way companies do business. From the beginning of this global health crisis, our first priority has been the safety and well-being of our employees. We continue to monitor the developments associated with the COVID-19 pandemic and its effects on our employees, customers, supply chain and distribution channels. The ongoing impact of the pandemic depends on a number of factors including the severity and duration of the pandemic and the extent and severity of the impact on our customers, which is uncertain and unpredictable. Our future results of operations and cash flows may suffer adverse effects from delays in payments on outstanding accounts receivable, potential manufacturing, distribution and supply chain disruptions and uncertain demand, and effects of any actions we may take to address financial and operational challenges our customers may face. Our future results will be heavily determined by timely rollout of the vaccines, effectiveness of the vaccines, the duration of the pandemic, its geographic spread, further business disruptions and the overall impact on the global economy. Other risks and uncertainties that we face include, but are not limited to: ● postponement or cancellation of MRI medical procedures and their uncertain return which adversely impacts our business; ● potential temporary or prolonged closure of our office and production facility; ● the health of our employees and ability to meet staffing needs; ● potential new or continued governmental actions that may limit employees’ ability to work; ● civil unrest relating to government, corporate and societal responses to the pandemic; ● volatility in economic conditions and the financial markets, and ● other unanticipated effects that remain unknown. We are actively managing our response to the COVID-19 pandemic and working with our customers, distributors, vendors, and suppliers and assessing the potential effects to our financial position, results of operations and cash flows. As of the date of the issuance of these financial statements, the extent to which COVID-19 may materially impact our financial condition, liquidity, or results of operations in future periods remains uncertain. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements Recently Issued Accounting Pronouncements to be Implemented In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Codification Improvements to Topic 326, Financial Instruments - Credit Losses Codification Improvements to Topic 326, Financial Instruments - Credit Losses Financial Instruments - Credit Losses (Topic 326): Targeted Transition Relief Accounting Pronouncements Implemented in 2021 In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes |
Revenue Recognition (Tables)
Revenue Recognition (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Revenue Recognition | |
Schedule of disaggregation of revenue by geographic region and revenue type | Revenue information by geographic region is as follows: Three Months Ended March 31, 2021 2020 (unaudited) United States $ 7,272,830 $ 6,322,106 International 1,951,166 2,355,435 Total revenue $ 9,223,996 $ 8,677,541 Revenue information by type is as follows: Three Months Ended March 31, 2021 2020 (unaudited) Devices: MRI compatible IV infusion pump system $ 3,503,347 $ 2,664,834 MRI compatible patient vital signs monitoring systems 2,603,830 2,888,703 Total Devices revenue 6,107,177 5,553,537 Disposables, services and other 2,635,466 2,662,713 Amortization of extended warranty agreements 481,353 461,291 Total revenue $ 9,223,996 $ 8,677,541 |
Schedule of contract liabilities and changes in the contract liabilities | Our contract liabilities consist of: March 31, December 31, 2021 2020 (unaudited) Advance payments from customers $ 191,227 $ 85,590 Shipments in-transit 218,100 35,013 Extended warranty agreements 3,877,604 4,134,069 Total $ 4,286,931 $ 4,254,672 Changes in the contract liabilities during the periods presented are as follows: Deferred Revenue Contract liabilities, December 31, 2020 $ 4,254,672 Increases due to cash received from customers 681,433 Decreases due to recognition of revenue (649,174) Contract liabilities, March 31, 2021 $ 4,286,931 Deferred Revenue Contract liabilities, December 31, 2019 $ 4,301,887 Increases due to cash received from customers 779,048 Decreases due to recognition of revenue (492,924) Contract liabilities, March 31, 2020 $ 4,588,011 |
Basic and Diluted Net Income _2
Basic and Diluted Net Income per Share (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Basic and Diluted Net Income per Share | |
Schedule of computation of basic and diluted net income per share | Three Months Ended March 31, 2021 2020 (unaudited) Net income $ 1,386,849 $ 1,769,211 Weighted-average shares outstanding — Basic 12,310,577 11,891,428 Effect of dilutive securities: Stock options 189,933 414,439 Restricted stock units 20,769 59,738 Weighted-average shares outstanding — Diluted 12,521,279 12,365,605 Basic net income per share $ 0.11 $ 0.15 Diluted net income per share $ 0.11 $ 0.14 |
Schedule of stock options and restricted stock units excluded from the calculation of diluted net income per share | Three Months Ended March 31, 2021 2020 (unaudited) Anti-dilutive stock options and restricted stock units 4,902 62,904 |
Inventory (Tables)
Inventory (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Inventory | |
Schedule of inventory | March 31, December 31, 2021 2020 (unaudited) Raw materials $ 3,502,986 $ 3,210,815 Work in process 292,644 207,807 Finished goods 980,607 653,038 Inventory before allowance for excess and obsolete 4,776,237 4,071,660 Allowance for excess and obsolete (135,681) (137,673) Total $ 4,640,556 $ 3,933,987 |
Property and Equipment (Tables)
Property and Equipment (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Property and Equipment | |
Schedule of property and equipment | March 31, December 31, 2021 2020 (unaudited) Computer software and hardware $ 721,008 $ 705,811 Furniture and fixtures 1,226,865 1,226,113 Leasehold improvements 230,351 230,351 Machinery and equipment 1,842,037 1,823,835 Tooling in-process 569,365 470,446 4,589,626 4,456,556 Accumulated depreciation (2,463,547) (2,336,408) Total $ 2,126,079 $ 2,120,148 |
Schedule of property and equipment, net, information by geographic region | March 31, December 31, 2021 2020 (unaudited) United States $ 1,855,369 $ 1,832,894 International 270,710 287,254 Total property and equipment, net $ 2,126,079 $ 2,120,148 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Intangible Assets | |
Summary of the components of intangible asset balances | March 31, December 31, 2021 2020 (unaudited) Patents — in use $ 362,162 $ 362,162 Patents — in process 73,648 69,733 Internally developed software — in use 872,218 872,253 Internally developed software — in process 299,357 261,622 Trademarks 27,247 27,247 1,634,632 1,593,017 Accumulated amortization (658,250) (632,132) Total $ 976,382 $ 960,885 |
Schedule of expected annual amortization expense related to intangible assets (excludes in process intangible assets) | Nine months ending December 31, 2021 $ 75,313 2022 $ 99,700 2023 $ 99,189 2024 $ 98,787 2025 $ 95,849 2026 $ 84,830 |
Investments (Tables)
Investments (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Investments | |
Summary of available-for-sale securities | March 31, 2021 Gross Gross Unrealized Unrealized Fair Cost Gains Losses Value U.S. corporate bonds $ 1,863,382 $ 39,558 $ — $ 1,902,940 December 31, 2020 Gross Gross Unrealized Unrealized Fair Cost Gains Losses Value U.S. corporate bonds $ 1,863,382 $ 45,986 $ — $ 1,909,368 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Fair Value Measurements | |
Schedule of the fair value of assets and liabilities subject to recurring fair value measurements | Fair Value at March 31, 2021 Quoted Prices Significant in Active Other Significant Market for Observable Unobservable Fair Identical Assets Inputs Inputs Value (Level 1) (Level 2) (Level 3) U.S. corporate bonds $ 1,902,940 $ — $ 1,902,940 $ — Fair Value at December 31, 2020 Quoted Prices Significant in Active Other Significant Market for Observable Unobservable Fair Identical Assets Inputs Inputs Value (Level 1) (Level 2) (Level 3) U.S. corporate bonds $ 1,909,368 $ — $ 1,909,368 $ — |
Accumulated Other Comprehensi_2
Accumulated Other Comprehensive Income (Loss) (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Accumulated Other Comprehensive Income | |
Schedule of components of accumulated other comprehensive loss, net of tax | The components of accumulated other comprehensive income, net of tax, for the three months ended March 31, 2021 and 2020 are as follows: Unrealized (Losses) Gains on Available-For-Sale Securities Balance at December 31, 2020 $ 37,087 Loss on available-for-sale securities, net (4,869) Balance at March 31, 2021 $ 32,218 Balance at December 31, 2019 $ 30,374 Gains on available-for-sale securities, net 10,433 Balance at March 31, 2020 $ 40,807 |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Stock-Based Compensation | |
Schedule of stock-based compensation | Three Months Ended March 31, 2021 2020 (unaudited) Cost of revenue $ 54,211 $ 58,254 General and administrative 180,204 362,152 Sales and marketing 81,935 130,955 Research and development 31,391 17,597 Total $ 347,741 $ 568,958 |
Summary of stock options and restricted stock units activity | The following table presents a summary of our stock-based compensation activity for the three months ended March 31, 2021 (shares): Performance Based Stock Restricted Restricted Options Stock Units Stock Units Outstanding beginning of period 230,510 151,139 11,891 Awards granted — 8,920 — Awards exercised/vested (250) (5,157) — Awards canceled — (9,346) (2,546) Outstanding end of period 230,260 145,556 9,345 |
Leases (Tables)
Leases (Tables) | 3 Months Ended |
Mar. 31, 2021 | |
Leases | |
Schedule of operating lease cost | Three Months Ended March 31, 2021 2020 Cost of revenue $ 51,095 $ 46,535 General and administrative 50,556 46,044 Sales and marketing 2,859 2,604 Research and development 7,922 7,215 Total $ 112,432 $ 102,398 |
Schedule of maturity of operating lease liability | Nine months ending December 31, 2021 $ 307,197 2022 409,596 2023 409,596 2024 409,596 2025 409,596 Thereafter 1,399,454 Total lease payments 3,345,035 Imputed interest (692,502) Present value of lease liability $ 2,652,533 |
Basis of Presentation (Details)
Basis of Presentation (Details) | 3 Months Ended |
Mar. 31, 2021segment | |
Basis of Presentation | |
Number of reportable segment | 1 |
Revenue Recognition - Informati
Revenue Recognition - Information by geographic region (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Contract Liabilities | ||
Total revenue | $ 9,223,996 | $ 8,677,541 |
United States | ||
Contract Liabilities | ||
Total revenue | 7,272,830 | 6,322,106 |
International | ||
Contract Liabilities | ||
Total revenue | $ 1,951,166 | $ 2,355,435 |
Revenue Recognition - Informa_2
Revenue Recognition - Information by Type (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Disaggregation of Revenue | ||
Total Devices revenue | $ 6,107,177 | $ 5,553,537 |
Disposables, service and other | 2,635,466 | 2,662,713 |
Amortization of extended warranty agreements | 481,353 | 461,291 |
Total revenue | 9,223,996 | 8,677,541 |
MRI Compatible IV Infusion Pump Systems | ||
Disaggregation of Revenue | ||
Total Devices revenue | 3,503,347 | 2,664,834 |
MRI Compatible Patient Vital Signs Monitoring Systems | ||
Disaggregation of Revenue | ||
Total Devices revenue | $ 2,603,830 | $ 2,888,703 |
Revenue Recognition - Contract
Revenue Recognition - Contract Liabilities (Details) - USD ($) | 3 Months Ended | |||
Mar. 31, 2021 | Mar. 31, 2020 | Mar. 31, 2021 | Dec. 31, 2020 | |
Deferred revenue | ||||
Advance payments from customers | $ 191,227 | $ 85,590 | ||
Shipments in-transit | 218,100 | 35,013 | ||
Extended warranty agreements | 3,877,604 | 4,134,069 | ||
Total | $ 4,286,931 | $ 4,588,011 | $ 4,286,931 | $ 4,254,672 |
Changes in contract liabilities | ||||
Contract liabilities at beginning of the year | 4,254,672 | 4,301,887 | ||
Increases due to cash received from customers | 681,433 | 779,048 | ||
Decreases due to recognition of revenue | (649,174) | (492,924) | ||
Contract liabilities at end | $ 4,286,931 | $ 4,588,011 |
Revenue Recognition - Capitaliz
Revenue Recognition - Capitalized Contract Costs (Details) - USD ($) | Mar. 31, 2021 | Dec. 31, 2020 |
Revenue Recognition | ||
Capitalized contract costs | $ 352,308 | $ 384,367 |
Basic and Diluted Net Income _3
Basic and Diluted Net Income per Share (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Basic and Diluted Net Income per Share | ||
Net income | $ 1,386,849 | $ 1,769,211 |
Weighted-average shares outstanding - Basic (in shares) | 12,310,577 | 11,891,428 |
Effect of dilutive securities: | ||
Stock Options | 189,933 | 414,439 |
Restricted Stock Units | 20,769 | 59,738 |
Weighted-average shares outstanding - Diluted (in shares) | 12,521,279 | 12,365,605 |
Basic net income per share (in dollars per share) | $ 0.11 | $ 0.15 |
Diluted net income per share (in dollars per share) | $ 0.11 | $ 0.14 |
Anti-dilutive stock | ||
Anti-dilutive stock options and restricted stock units | 4,902 | 62,904 |
Inventory (Details)
Inventory (Details) - USD ($) | Mar. 31, 2021 | Dec. 31, 2020 |
Inventory | ||
Raw materials | $ 3,502,986 | $ 3,210,815 |
Work in process | 292,644 | 207,807 |
Finished goods | 980,607 | 653,038 |
Inventory before allowance for excess and obsolete | 4,776,237 | 4,071,660 |
Allowance for excess and obsolete | (135,681) | (137,673) |
Total | $ 4,640,556 | $ 3,933,987 |
Property and Equipment (Details
Property and Equipment (Details) - USD ($) | 3 Months Ended | ||
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | |
Property and equipment | |||
Property and equipment, gross | $ 4,589,626 | $ 4,456,556 | |
Accumulated depreciation | (2,463,547) | (2,336,408) | |
Total | 2,126,079 | 2,120,148 | |
Depreciation and amortization expense of property and equipment | 127,139 | $ 126,308 | |
Computer software and hardware | |||
Property and equipment | |||
Property and equipment, gross | 721,008 | 705,811 | |
Furniture and fixtures | |||
Property and equipment | |||
Property and equipment, gross | 1,226,865 | 1,226,113 | |
Leasehold improvements | |||
Property and equipment | |||
Property and equipment, gross | 230,351 | 230,351 | |
Machinery and equipment | |||
Property and equipment | |||
Property and equipment, gross | 1,842,037 | 1,823,835 | |
Tooling in-process | |||
Property and equipment | |||
Property and equipment, gross | $ 569,365 | $ 470,446 |
Property and Equipment - Geogra
Property and Equipment - Geographic information (Details) - USD ($) | Mar. 31, 2021 | Dec. 31, 2020 |
Property and equipment | ||
Total property and equipment, net | $ 2,126,079 | $ 2,120,148 |
United States | ||
Property and equipment | ||
Total property and equipment, net | 1,855,369 | 1,832,894 |
International | ||
Property and equipment | ||
Total property and equipment, net | $ 270,710 | $ 287,254 |
Intangible Assets (Details)
Intangible Assets (Details) - USD ($) | 3 Months Ended | ||
Mar. 31, 2021 | Mar. 31, 2020 | Dec. 31, 2020 | |
Intangible assets | |||
Intangible Assets, gross | $ 1,634,632 | $ 1,593,017 | |
Accumulated amortization | (658,250) | (632,132) | |
Total | 976,382 | 960,885 | |
Amortization expense of intangible assets | 26,118 | $ 22,491 | |
Expected annual amortization expense | |||
Nine months ending December 31, 2021 | 75,313 | ||
2022 | 99,700 | ||
2023 | 99,189 | ||
2024 | 98,787 | ||
2025 | 95,849 | ||
2026 | 84,830 | ||
Patents - in use | |||
Intangible assets | |||
Intangible Assets, gross | 362,162 | 362,162 | |
Patents - in process | |||
Intangible assets | |||
Intangible Assets, gross | 73,648 | 69,733 | |
Internally developed software - in use | |||
Intangible assets | |||
Intangible Assets, gross | 872,218 | 872,253 | |
Internally developed software - in process | |||
Intangible assets | |||
Intangible Assets, gross | 299,357 | 261,622 | |
Trademarks | |||
Intangible assets | |||
Intangible Assets, gross | $ 27,247 | $ 27,247 |
Investments (Details)
Investments (Details) - U.S. corporations - USD ($) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2021 | Dec. 31, 2020 | |
Investments | ||
Cost | $ 1,863,382 | $ 1,863,382 |
Gross Unrealized Gains | 39,558 | 45,986 |
Fair Value | $ 1,902,940 | $ 1,909,368 |
Fair Value Measurements (Detail
Fair Value Measurements (Details) - USD ($) | Mar. 31, 2021 | Dec. 31, 2020 |
Fair Value Measurements | ||
Fair value assets, amount transferred between measurement levels | $ 0 | |
Fair value liabilities, amount transferred between measurement levels | $ 0 | |
Recurring | U.S. corporations | ||
Fair Value Measurements | ||
Total | 1,902,940 | 1,909,368 |
Recurring | Significant Other Observable Inputs (Level 2) | U.S. corporations | ||
Fair Value Measurements | ||
Total | $ 1,902,940 | $ 1,909,368 |
Accumulated Other Comprehensi_3
Accumulated Other Comprehensive Income (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Component of accumulated other comprehensive loss | ||
Balance at the beginning | $ 37,087 | $ 30,374 |
Gains (Loss) on available-for-sale securities, net | (4,869) | 10,433 |
Balance at the end | $ 32,218 | $ 40,807 |
Stock-Based Compensation (Detai
Stock-Based Compensation (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Stock-Based Compensation | ||
Total stock-based compensation expense | $ 347,741 | $ 568,958 |
Cost of revenue | ||
Stock-Based Compensation | ||
Total stock-based compensation expense | 54,211 | 58,254 |
General and administrative | ||
Stock-Based Compensation | ||
Total stock-based compensation expense | 180,204 | 362,152 |
Sales and marketing | ||
Stock-Based Compensation | ||
Total stock-based compensation expense | 81,935 | 130,955 |
Research and development | ||
Stock-Based Compensation | ||
Total stock-based compensation expense | $ 31,391 | $ 17,597 |
Stock-Based Compensation - Stoc
Stock-Based Compensation - Stock Options and Restricted Stock Units Activity (Details) - USD ($) | 1 Months Ended | 3 Months Ended |
Dec. 31, 2020 | Mar. 31, 2021 | |
Stock Options | ||
Stock Options | ||
Outstanding beginning of period (in shares) | 230,510 | |
Options exercised (in shares) | (250) | |
Outstanding end of period (in shares) | 230,510 | 230,260 |
Restricted Stock Units | ||
Stock-Based Compensation | ||
Options granted (in shares) | 8,920 | |
Unrecognized compensation cost related to unvested restricted stock units | $ 2,867,766 | |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 2 years 8 months 12 days | |
Stock Options | ||
Outstanding beginning of period (in shares) | 151,139 | |
Options granted (in shares) | 8,920 | |
Options exercised (in shares) | (5,157) | |
Options cancelled (in shares) | (9,346) | |
Outstanding end of period (in shares) | 151,139 | 145,556 |
Performance-Based Restricted Stock Units ("PSUs") | ||
Stock-Based Compensation | ||
Unrecognized compensation cost related to unvested restricted stock units | $ 247,002 | |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 2 years 8 months 12 days | |
Weighted-average grant-date fair value of options granted (in dollars per share) | $ 29.53 | |
Stock Options | ||
Outstanding beginning of period (in shares) | 11,891 | |
Options cancelled (in shares) | (2,546) | |
Outstanding end of period (in shares) | 11,891 | 9,345 |
Summary of weighted average assumptions used to estimate the fair value of stock option grants | ||
Volatility (as a percent) | 51.00% | |
Expected term (years) | 3 years | |
Risk- free interest rate (as a percent) | 0.20% | |
Dividend yield (as a percent) | 0.00% | |
Performance-Based Restricted Stock Units ("PSUs") | Long-Term Incentive Plan ("LTIP") | ||
Stock-Based Compensation | ||
Options granted (in shares) | 11,891 | |
Stock Options | ||
Options granted (in shares) | 11,891 | |
Performance-Based Restricted Stock Units ("PSUs") | Minimum | ||
Stock-Based Compensation | ||
Payout percentage for participants. | 0.00% | |
Summary of weighted average assumptions used to estimate the fair value of stock option grants | ||
Volatility (as a percent) | 39.90% | |
Dividend yield (as a percent) | 0.00% | |
Performance-Based Restricted Stock Units ("PSUs") | Maximum | ||
Stock-Based Compensation | ||
Payout percentage for participants. | 200.00% | |
Summary of weighted average assumptions used to estimate the fair value of stock option grants | ||
Volatility (as a percent) | 89.40% | |
Dividend yield (as a percent) | 1.23% |
Income Taxes (Details)
Income Taxes (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Reconciliation of the statutory U.S. federal tax rate to effective rate | ||
Provision for income tax expense (benefit) | $ 384,494 | $ (933,474) |
Effective tax rate (as a percent) | 21.70% | (111.70%) |
Leases (Details)
Leases (Details) | 1 Months Ended | 3 Months Ended |
Jan. 31, 2014USD ($) | Mar. 31, 2021item | |
Leases | ||
Number of material lease contract outstanding | item | 1 | |
Lessee, operating lease, existence of option to extend | true | |
Lessee, operating lease, existence of residual value guarantee | false | |
Susi, LLC | Winter Springs, Florida Facility | ||
Leases | ||
Monthly base rent | $ | $ 34,133 | |
Number of successive renewal terms of lease | 1 | |
Renewal term of lease beginning in 2019 | 5 years | |
Renewal term of lease beginning in 2024 | 5 years | |
Renewal term lease thereafter | 1 year | |
Remaining lease term (in years) | 8 years 2 months 12 days |
Leases - Operating Lease Cost (
Leases - Operating Lease Cost (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2021 | Mar. 31, 2020 | |
Leases | ||
Operating lease cost | $ 112,432 | $ 102,398 |
Cost of revenue | ||
Leases | ||
Operating lease cost | 51,095 | 46,535 |
General and administrative | ||
Leases | ||
Operating lease cost | 50,556 | 46,044 |
Sales and marketing | ||
Leases | ||
Operating lease cost | 2,859 | 2,604 |
Research and development | ||
Leases | ||
Operating lease cost | $ 7,922 | $ 7,215 |
Leases - Maturity of Lease Liab
Leases - Maturity of Lease Liabilities (Details) | Mar. 31, 2021USD ($) |
Operating leases | |
Nine months ending December 31, 2021 | $ 307,197 |
2022 | 409,596 |
2023 | 409,596 |
2024 | 409,596 |
2025 | 409,596 |
Thereafter | 1,399,454 |
Total lease payments | 3,345,035 |
Imputed interest | (692,502) |
Present value of lease liability | $ 2,652,533 |
Commitments and Contingencies (
Commitments and Contingencies (Details) - USD ($) | Mar. 31, 2021 | Dec. 31, 2020 |
Purchase commitments | ||
Purchase commitments | $ 3,185,649 | $ 3,089,103 |